Team’s potential lung cancer therapy lands award from SBIRby Liz Entman Sep. 27, 2018, 3:14 PM
A potential cancer drug aimed at enhancing the effectiveness of ionizing radiation in lung cancer patients is a step closer to development with funding support from the Small Business Innovation Research (SBIR) program.
Michael Freeman, PhD, professor of Radiation Oncology, is co-principal investigator with Diane Keeney, PhD, of Cumberland Emerging Technologies (CET) on the $2 million federal research award.
The compound, YTR107, is a small molecule Freeman and colleagues identified that has been shown to radiosensitize non-small cell lung cancer cell lines. The award will support development of a formulated version of the compound for treatment of stage IIb and stage III non-small cell lung cancer in humans.